UK Legal Firms Investigate Claims Against Pfizer Over Depo-Provera Risks
Several prominent UK law firms are actively considering launching legal action against pharmaceutical giant Pfizer. This potential litigation centres on the contraceptive injection Depo-Provera, which has been linked in multiple studies to a significantly higher relative risk of developing meningiomas, a type of benign brain tumour.
Global Usage and Emerging Health Concerns
Depo-Provera is a high-dose synthetic progesterone administered via injection every three months. It is prescribed for contraception and other menstrual symptoms. According to United Nations estimates, approximately 74 million women worldwide use injectable contraceptives, with about 3.1% of UK women aged 15 to 49 among them.
While meningiomas are typically non-cancerous, they can lead to severe health complications. These include seizures, blindness, hearing loss, persistent headaches, and significant memory problems. The overall risk remains low, but the elevated relative risk has prompted serious medical and legal scrutiny.
Law Firms Gather Evidence and Client Testimonies
Firms such as Austen Hays, Fletchers, and Leigh Day are in the preliminary stages of assessing the legal basis for claims. Austen Hays has reported being approached by at least 30 women who developed meningiomas following prolonged use of Depo-Provera.
Chaya Hanoomanjee, a partner at Austen Hays, stated: "Their lives have been considerably impacted due to having brain tumours, with consequences such as loss of vision and, in one case, a woman having to terminate her pregnancy. The duty here lies with Pfizer to ensure a drug is safe and to update warnings and contraindications as soon as new risks become known."
Jill Paterson from Leigh Day added: "We know the devastating impact meningiomas can have on women’s lives and are assessing the strength of any potential case of those affected. We are investigating the potential for a legal claim against the manufacturer."
Parallel Litigation in the United States
This UK legal development coincides with extensive litigation in the United States, where thousands of women are suing Pfizer for compensation. Three American law firms are leading a federal case representing approximately 2,500 women, with the first trial scheduled for December.
US lawyers argue that Pfizer has been aware of the meningioma risk since at least 2015 but failed to adequately warn patients, medical professionals, and the US Food and Drug Administration. Pfizer has not admitted liability and is contesting these claims.
Personal Accounts Highlight Devastating Impacts
The human cost of these health issues is starkly illustrated by individual stories. In the US, Sandra Somarakis is suing Pfizer after developing a meningioma following about 15 years of Depo-Provera use. Diagnosed in 2008, she underwent surgery and later required further surgery and radiation treatment.
"To this day, I can’t open my mouth wide," Somarakis says. "My left eyeball still pops out. It’s sore, it’s watery. It’s hard to remember people’s names, I get lost easily."
In the UK, Claire Buck, a 47-year-old foster carer from Surrey, believes the injection contributed to her meningioma. After brain surgery, she had a metal plate inserted and nearly died from post-operative shock.
"I’m terrified of hospitals, I live in constant fear the tumour will start to grow again and I can’t cope with crowds or busy spaces – I worry someone might hit my head," she explained, detailing ongoing symptoms like chewing muscle atrophy, glaucoma, and memory issues.
Another UK woman, referred to as Emma (57), took Depo-Provera for 15 years until 2019 and was diagnosed with meningiomas in 2024 after developing seizures. She now suffers from fatigue and cognitive problems, fearing recurrence and potential progression to brain cancer.
Pfizer's Response and Safety Assurance
A spokesperson for Pfizer emphasised: "Patient safety is our top priority. We conduct rigorous and continuous monitoring of all our medicines, including assessments of reported adverse events, in collaboration with health authorities around the globe. Depo-Provera has been approved in more than 60 countries over the last 30 years, has a well-established efficacy and safety profile and has been a treatment option for millions of patients during that time."
The company advises individuals to consult healthcare professionals if they have concerns or experience side effects.
